Globus Medical (GMED) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for June 4, 2025, at Valley Forge Business Center in Audubon, PA.
Shareholders can vote online, by phone, email, or in person; deadline for online voting is June 3, 2025.
Proxy materials, including the Notice, Proxy Statement, and Form 10-K, are available online or by request.
Voting matters and shareholder proposals
Election of four directors: David C. Paul, Daniel T. Lemaitre, Leslie V. Norwalk, and Ann D. Rhoads.
Approval of an amendment to the 2021 Equity Incentive Plan.
Ratification of Deloitte & Touche LLP as independent auditor for the year ending December 31, 2025.
Advisory vote on executive compensation (Say-on-Pay Vote).
Advisory vote on the frequency of Say-on-Pay votes, with the board recommending a 1-year frequency.
Board of directors and corporate governance
Board recommends voting "For" all director nominees and all proposals.
Proxy is solicited on behalf of the Board of Directors; if no instructions are given, proxies will vote as recommended by the board.
Latest events from Globus Medical
- Record 2025 growth, raised 2026 EPS guidance, and strong cash flow driven by spine and tech.GMED
Q4 202525 Feb 2026 - Q2 net sales jumped 115.9% to $629.7M, with raised 2024 guidance and strong integration progress.GMED
Q2 20242 Feb 2026 - Q3 net sales up 63% to $625.7M, with record EPS and raised 2024 guidance.GMED
Q3 202416 Jan 2026 - Integration, innovation, and strategic acquisitions drive growth in robotics and spine care.GMED
CG 2025 Musculoskeletal Conference20 Dec 2025 - Record sales and profitability in 2024 set the stage for continued growth in 2025.GMED
Q4 202411 Dec 2025 - Proxy covers director elections, equity plan changes, auditor ratification, and executive pay votes.GMED
Proxy Filing1 Dec 2025 - Q2 net sales up 18.4% to $745.3M, GAAP net income $202.8M, and record non-GAAP EPS.GMED
Q2 202523 Nov 2025 - Record net income and cash flow in Q1 2025 despite a 1.4% sales decline.GMED
Q1 202519 Nov 2025 - Q3 2025 delivered record sales, doubled net income, and raised full-year guidance.GMED
Q3 202513 Nov 2025